Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative

Neumayr, Andreas; Muñóz, José; Schunk, Mirjam; Bottieau, Emmanuel; Cramer, Jakob P.; Calleri, Guido; López‐Vélez, Rogelio; Angheben, Andrea; Zöller, Thomas; Visser, Leo G.; Serre-Delcor, Núria; Genton, Blaise; Castelli, Francesco; Esbroeck, Marjan Van; Matteelli, Alberto; Rochat, Laurence; Sulleiro, Elena; Kurth, Florian; Gobbi, Federico; Norman, Francesca; Torta, Ilaria; Clerinx, Jan; Poluda, David; Martínez-Priego, Llúcia; Calvo-Cano, Antonia; Sánchez-Seco, María Paz; Wilder‐Smith, Annelies; Hatz, Christoph; Franco, Leticia; TropNet, for

doi:10.2807/1560-7917.es.2017.22.1.30433

Cited by 48 publications

(29 citation statements)

References 31 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Imported cases of DENV infection have been reported in several European countries in recent years (Neumayr et al ., ). In 2010, two different autochthonous outbreaks occurred in, respectively, France (La Ruche et al ., ) and Croatia (Gjenero‐Margan et al ., ).…”

Section: Introductionmentioning

confidence: 97%

Experimental study of the susceptibility of a European Aedes albopictus strain to dengue virus under a simulated Mediterranean temperature regime

Brustolin

Santamaría

Napp

et al. 2018

Medical Vet Entomology

View full text Add to dashboard Cite

Dengue virus (DENV) has re-emerged in Europe driven by the geographic expansion of the mosquito species Aedes albopictus and Aedes aegypti (Diptera: Culicidae) and the introduction of the virus by viraemic travellers. In the present study, the vector competence (VC) of Ae. albopictus collected in Catalonia (northeast Spain) was evaluated for two different DENV strains, DENV-1 and DENV-2, the serotypes responsible for all outbreaks of dengue that have occurred in Europe. Mosquitoes were reared under environmental conditions mimicking the mean temperature and humidity recorded in July on the Mediterranean coast of Catalonia. Mosquitoes were fed on an artificial infectious bloodmeal and, at 14 days post-exposure, infection, disseminated infection and transmission rates (IR, DIR, TR) and transmission efficiency (TE) were determined by testing the virus in the body, legs and saliva. The tested Ae. albopictus strain was found to be susceptible to both DENV-1 and DENV-2 and to be able to transmit DENV-1. This is the first time that the VC of Ae. albopictus for DENV has been tested in Europe in this specific context (i.e. mimicking the Mediterranean temperature and humidity recorded in Catalonia in July). This study confirms the potential of Ae. albopictus to start autochthonous DENV transmission cycles in the Mediterranean basin.

show abstract

Section: Introductionmentioning

confidence: 97%

Experimental study of the susceptibility of a European Aedes albopictus strain to dengue virus under a simulated Mediterranean temperature regime

Brustolin

Santamaría

Napp

et al. 2018

Medical Vet Entomology

View full text Add to dashboard Cite

show abstract

“…DENV is endemic in the tropical areas of Asia, Latin America, and the Pacific and circulates across Africa. Recent travel‐imported and local outbreaks in the United States and Europe have also been reported …”

Section: Dengue Virusmentioning

confidence: 97%

Emerging arboviruses and implications for pediatric transplantation: A review

Freeman

Coyne

Green

et al. 2018

Pediatric Transplantation

View full text Add to dashboard Cite

Recent years have brought a rise in newly emergent viral infections, primarily in the form of previously known arthropod-transmitted viruses that have increased significantly in both incidence and geographical range. Of particular note are DENV, CHIKV, and ZIKV, which are transmitted mostly by Aedes species of mosquitoes that exhibit a wide and increasing global distribution. Being important pathogens for the general population, these viruses have the potential to be devastating in the international transplant community, with graft rejection and death as possible outcomes of infection. In this review, we discuss the current state of knowledge for these viruses as well as repercussions of infection in the solid organ and HSCT population, with a focus, when possible, on pediatric patients. K E Y W O R D S arboviruses, chikungunya virus, dengue virus, pediatric transplantation, transplantation, Zika virus 2 of 12 |

show abstract

“…However, immunogenicity and safety data up to the age of 45 are available [69]. EMA has endorsed the age range from 9 to 45, but FDA has restricted the use of Dengvaxia to the age range of 9 to 16 [27,70,71].…”

Section: Indicated Age Range For Cyd-tdv In Travelersmentioning

confidence: 99%

The first licensed dengue vaccine: can it be used in travelers?

Wilder‐Smith

2019

Current Opinion in Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Purpose of review: The first dengue vaccine (Dengvaxia®) was endorsed by the European Medicine Agency and the US Food and Drug Administration. Given the excess risk of severe dengue in seronegative vaccinees, use is restricted to seropositive individuals. Dengvaxia confers high protection against severe dengue in seropositive vaccinees. Recent findings: With increasing global travel, the probability of travelers being seropositive increases. Such seropositive travelers may be at increased risk of severe dengue as a result of a second dengue infection during repeat travel. Nevertheless, the use of Dengvaxia in travelers requires a careful analysis of all the factors. Seropositive travelers only present a minority of all travelers. A validated rapid diagnostic test to screen for dengue serostatus is not yet available. Such a test should be highly specific to avoid inadvertent vaccination of seronegative individuals. The 3-dose regimen precludes the use in most travelers who tend to present at travel clinics less than 6 weeks prior to departure. Furthermore, questions about potential sub-optimal immunogenicity in seropositives in non-endemic settings, and the need and timing of boosters remain unanswered. Conclusions: Although there could potentially be substantial protection against severe dengue in seropositive travelers, Dengvaxia is far from an ideal travel vaccine.

show abstract

Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative

Cited by 48 publications

References 31 publications

Experimental study of the susceptibility of a European Aedes albopictus strain to dengue virus under a simulated Mediterranean temperature regime

Experimental study of the susceptibility of a European Aedes albopictus strain to dengue virus under a simulated Mediterranean temperature regime

Emerging arboviruses and implications for pediatric transplantation: A review

The first licensed dengue vaccine: can it be used in travelers?

Contact Info

Product

Resources

About